| Developers: | Sanofi |
| Branches: | Pharmaceuticals, medicine, healthcare |
Content |
History
2022: Sanofi will pay 450 thousand euros to the family where the child with autism was born due to the drug
In mid-May 2022, the French pharmaceutical laboratory Sanofi was ordered to pay €450 thousand in compensation to a family whose child was born with developmental disorders (autism) caused by the use of Depakine for epilepsy by his mother.
A court in France ordered the Sanofi laboratory to pay compensation after it turned out that the girl was exposed to Depakine (Depakin) during prenatal development. The mother had been taking this medication for epilepsy since 1982, when she was pregnant in 2004, she took four pills a day. At the age of seven months, the girl was hospitalized for bronchiolitis, and then it was noticed that she had a general delay in development, and after that a delay in development was observed throughout childhood.
In 2016, her parents went to court against Sanofi. The court found that the laboratory was aware that the drug could cause developmental delay and autism-type difficulties, at least since 2003. The court ruled that the laboratory was obliged to indicate this in the instructions for the drug. Depakin, whose active ingredient is sodium valproate, has been used to treat epilepsy and bipolar disorders since 1967. The drug is also sold under the trade names Depakote and Depamide for the treatment of bipolar disorder, as well as under generic names and is sometimes used to treat severe migraines.
However, when taken during pregnancy, there is a risk of serious side effects for unborn babies. Depakine can cause physical deformities, problems with the cardiovascular system and spine, and neurodevelopment problems, autistic spectrum, delayed language learning in the developing fetus.
The court ruling, issued May 12, 2022, says Sanofi has known about the risks associated with this drug since at least 2003 and should have reported it to patients from that point on. Only in 2006, the company reported that it did not recommend using the drug during pregnancy, and warned patients to consult a doctor as soon as possible in case of pregnancy.[1]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |